Zentalis Pharmaceuticals Llc (ZNTL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zentalis Pharmaceuticals Llc (ZNTL) has a cash flow conversion efficiency ratio of -0.143x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.94 Million) by net assets ($216.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ZNTL equity to assets ratio to measure how much of total assets are equity-financed.
Zentalis Pharmaceuticals Llc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Zentalis Pharmaceuticals Llc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ZNTL cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Zentalis Pharmaceuticals Llc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zentalis Pharmaceuticals Llc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangzhou Tech-Long Packing Machine Co Ltd
SHE:002209
|
0.134x |
|
P-Duke Technology Co Ltd
TWO:8109
|
0.046x |
|
Panora Gayrimenkul Yatirim Ortakligi AS
IS:PAGYO
|
0.011x |
|
Gérard Perrier Industrie S.A.
PA:PERR
|
0.163x |
|
VT Industrial Technology Co Ltd
SHE:300707
|
0.049x |
|
G Willi-Food International Ltd
TA:WILC
|
0.034x |
|
Haymaker Acquisition Corp. 4
NYSE:HYAC
|
-0.215x |
|
SUNAC SERVIC.HLDGS HD-01
F:65D
|
N/A |
Annual Cash Flow Conversion Efficiency for Zentalis Pharmaceuticals Llc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Zentalis Pharmaceuticals Llc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see ZNTL stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $216.20 Million | $-125.25 Million | -0.579x | -14.32% |
| 2024-12-31 | $337.19 Million | $-170.86 Million | -0.507x | -6.65% |
| 2023-12-31 | $437.39 Million | $-207.82 Million | -0.475x | -25.94% |
| 2022-12-31 | $434.02 Million | $-163.75 Million | -0.377x | +10.76% |
| 2021-12-31 | $364.48 Million | $-154.09 Million | -0.423x | -62.33% |
| 2020-12-31 | $333.38 Million | $-86.83 Million | -0.260x | +54.48% |
| 2019-12-31 | $68.42 Million | $-39.14 Million | -0.572x | +23.79% |
| 2018-12-31 | $32.31 Million | $-24.25 Million | -0.751x | -- |
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosert… Read more